The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance.

Content Provider	Europe PMC
Author	Jiang, Shaowen Cai, Minghao Zhang, Zhenglan Qian, Cong Wang, Jiexiao Li, Ziqiang Guo, Qing Zhou, Huijuan Xin, Haiguang Cai, Wei Wang, Hui Guo, Simin Huang, Yan Xie, Qing
Copyright Year	2023
Abstract	Off-treatment HBsAg reversion occurs in a considerable number of chronic hepatitis B(CHB) patients after IFN(interferon)-induced HBsAg clearance. HBV vaccination protects the general population against HBV infection. However, it remains unclear whether HBV vaccination could prevent off-treatment HBsAg reversion in CHB patients with HBsAg clearance. CHB patients (n = 199) with HBsAg clearance were included in the current study, comprising spontaneous HBsAg clearance group (n = 51), NA (nucleoside/nucleotide analogues)-induced group (n = 36) and IFN-induced group (n = 112). Log-rank test was performed to compare the cumulative incidences of HBsAg reversion between groups. Cox regression model was used to identify the factors associated with off-treatment HBsAg reversion. The 5-year cumulative incidence of HBsAg reversion in IFN-induced group was significantly higher than that in NA-induced group or spontaneous group (27.6% vs. 3.3% vs. 8.1%, both p < .05). In IFN-induced group, 66.7% of CHB patients received HBV vaccination. The cumulative incidence of HBsAg reversion in individuals with strong responses to HBV vaccination (HBsAb level >100mIU/ml) was significantly lower than that in those with weak responses to HBV vaccination (HBsAb level ≤100mIU/ml) or without HBV vaccination in IFN-induced group (7.7% vs. 58.5% vs. 31.9%, both p < .05). Multivariate Cox regression analysis confirmed strong responses to HBV vaccination were independently associated with a lower cumulative incidence of HBsAg reversion after IFN-induced HBsAg clearance (HR = 0.246, 95%CI: 0.066–0.907, p = .035). HBV vaccination has potential to prevent off-treatment HBsAg reversion in CHB patients after IFN-induced HBsAg clearance via a sufficiently high level of HBsAb, helping clinicians optimize the clinical management of such patients.
Page Count	1
ISSN	21645515
Journal	Human Vaccines & Immunotherapeutics
Volume Number	19
PubMed Central reference number	PMC9980474
Issue Number	1
PubMed reference number	36683193
e-ISSN	2164554X
DOI	10.1080/21645515.2022.2161254
Language	English
Publisher	Taylor & Francis
Publisher Date	2023-01-22
Access Restriction	Open
Rights License	This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Subject Keyword	Chronic hepatitis B functional cure HBsAg clearance HBV vaccination interferon HBsAg reversion
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Pharmacology Immunology